title: Response to Bell: industry perspective.
authors.affiliation: Amylin Pharmaceuticals Inc, San Diego, California 92121, USA. abaron@amylin.com
authors.forename: A D
authors.initials: AD
authors.lastname: Baron
mesh_terms: D001675:Bioethics; D002986:Clinical Trials as Topic / Q000592:standards*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004345:Drug Industry; D004992:Ethics, Medical; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*
chemical_list: D007004:Hypoglycemic Agents